Ras-related and Estrogen-Regulated Growth inhibitor (RERG) and Ras-like 11 (RasL11)-like families. RERG (Ras-related and Estrogen- Regulated Growth inhibitor) and Ras-like 11 are members of a novel subfamily of Ras that were identified based on their behavior in breast and prostate tumors, respectively. RERG expression was decreased or lost in a significant fraction of primary human breast tumors that lack estrogen receptor and are correlated with poor clinical prognosis. Elevated RERG expression correlated with favorable patient outcome in a breast tumor subtype that is positive for estrogen receptor expression. In contrast to most Ras proteins, RERG overexpression inhibited the growth of breast tumor cells in vitro and in vivo. RasL11 was found to be ubiquitously expressed in human tissue, but down-regulated in prostate tumors. Both RERG and RasL11 lack the C-terminal CaaX prenylation motif, where a = an aliphatic amino acid and X = any amino acid, and are localized primarily in the cytoplasm. Both are believed to have tumor suppressor activity.
No pairwise interactions are available for this conserved domain.
Total Mutations Found: 112 Total Disease Mutations Found: 66 This domain occurred 109 times on human genes (196 proteins).
If you've navigated here from a protein, hovering over a position on the weblogo will display the corresponding protein position for that domain position.
The histograms below the weblogo indicate mutations found on the domain. Red is for disease (OMIM) and blue is for SNPs.
Functional Features are displayed as orange boxes under the histograms. You can choose which features are displayed in the box below.
Range on the Protein:
Protein ID Protein Position
Domain Position:
Feature Name:
Total Found:
Weblogos are Copyright (c) 2002 Regents of the University of California